INS and Hypoglycemia: Tirzepatide, at the three doses, was superior to titrated insulin degludec, with greater reductions in HbA1c and body weight at week 52 as well as a lower risk of hypoglycemia; all three tirzepatide doses decreased body weight (-7.5 kg to -12.9 kg), whereas insulin degludec increased body weight by 2.3 kg (48).